Placebo ophthalmic solution + DE-117 ophthalmic solution low + DE-117 ophthalmic solution high + Latanoprost ophthalmic solution 0.005%
Phase 2/3Completed 0 views this week 0 watching💤 Quiet
Interest: 38/100
38
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Open Angle Glaucoma
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Trial Timeline
Dec 6, 2015 → Feb 10, 2017
NCT ID
NCT02623738About Placebo ophthalmic solution + DE-117 ophthalmic solution low + DE-117 ophthalmic solution high + Latanoprost ophthalmic solution 0.005%
Placebo ophthalmic solution + DE-117 ophthalmic solution low + DE-117 ophthalmic solution high + Latanoprost ophthalmic solution 0.005% is a phase 2/3 stage product being developed by Santen Pharmaceutical for Primary Open Angle Glaucoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02623738. Target conditions include Primary Open Angle Glaucoma, Ocular Hypertension.
What happened to similar drugs?
20 of 20 similar drugs in Primary Open Angle Glaucoma were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
15
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02623738 | Phase 2/3 | Completed |
Competing Products
20 competing products in Primary Open Angle Glaucoma